| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 7. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | leuprorelin acetate (Lutrate®) |
| Formulation | 3.75 mg and 22.5 mg powder for prolonged-release suspension for injection |
| Reference number | 3129 |
| Indication | Palliative treatment of locally advanced or metastatic prostate cancer and for palliative treatment of hormone dependent advanced prostate cancer |
| Company | Mercury Pharma Group |
| BNF chapter | Endocrine system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 28/04/2016 |